696 related articles for article (PubMed ID: 27532364)
1. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
[TBL] [Abstract][Full Text] [Related]
4. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
[TBL] [Abstract][Full Text] [Related]
5. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753
[TBL] [Abstract][Full Text] [Related]
6. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
7.
Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
[TBL] [Abstract][Full Text] [Related]
8. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F
Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670
[TBL] [Abstract][Full Text] [Related]
9. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
[TBL] [Abstract][Full Text] [Related]
10. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
12. Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
Jia S; Miedel MT; Ngo M; Hessenius R; Chen N; Wang P; Bahreini A; Li Z; Ding Z; Shun TY; Zuckerman DM; Taylor DL; Puhalla SL; Lee AV; Oesterreich S; Stern AM
Oncology; 2018; 94(3):176-189. PubMed ID: 29306943
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
Transl Oncol; 2017 Oct; 10(5):766-771. PubMed ID: 28778025
[TBL] [Abstract][Full Text] [Related]
14. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Sim SH; Yang HN; Jeon SY; Lee KS; Park IH
Sci Rep; 2021 Mar; 11(1):5566. PubMed ID: 33692409
[TBL] [Abstract][Full Text] [Related]
17. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
19. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
[TBL] [Abstract][Full Text] [Related]
20. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
Gyanchandani R; Kota KJ; Jonnalagadda AR; Minteer T; Knapick BA; Oesterreich S; Brufsky AM; Lee AV; Puhalla SL
Oncotarget; 2017 Sep; 8(40):66901-66911. PubMed ID: 28978004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
